117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

G Dong,K.J Harrington,C Even,R Haddad,L.D Locati,C.J Yen,H Li,C.A Perez,I Xiang,Y Guo,H.R Kim,S Qiu

doi:10.1016/j.iotech.2023.100659

117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

G Dong, K.J Harrington + Show 10 more

https://doi.org/10.1016/j.iotech.2023.100659

Copy DOI

Journal: Immuno-Oncology and Technology

Publication Date: Dec 1, 2023

Affiliation: Institut Gustave Roussy, Dana-Farber Cancer Institute, National Cheng Kung University Hospital, BeiGene (China), Yonsei University, Severance Hospital, Fujian Provincial Cancer Hospital

#Neck Squamous Cell Carcinoma #Tislelizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Full Text